In this open-label , randomised , multicentre , phase @ study , patients from @ centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations , Eastern Cooperative Oncology Group performance status @ or @ , and no previous chemotherapy for advanced disease received erlotinib @ mg/day plus bevacizumab @ mg/kg every @ weeks or erlotinib @ mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity .